Immunogenicity and Safety of Vaccinations in Immunocompromised Persons

Completed

• Conditions: Spondylarthritis; Vasculitis; Arthritis, Rheumatoid
• Interventions: Biological: Hepatitis A vaccine and tetanus vaccine

• Registration Number: NCT01947465
• Lead Sponsor: University of Zurich

Brief Summary

Backgound and relevance of the project:

Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of contracting infections. The increased risk can be attributed to the immunological disorder itself, as well as to the immunosuppressive treatment. Vaccination against many infections is recommended in this patient group. However, the immunogenicity of vaccines may be reduced and may also be influenced by the administered treatment. Potential reactivation of the underlying disease triggered by vaccination is another important concern.

From the patients' and public health perspectives, an important task of physicians is giving advice on vaccines. Completing this task is often difficult, because data on the immunogenicity and safety of vaccines in these patient groups are scarce, especially with regard to treatment with new immunosuppressive medications, such as biological agents. Lastly and importantly, due to new therapeutic options, health among AIIRD patients has considerably improved and an increasing number of patients undertake overseas travel activities requiring additional vaccinations. In this context, reliable advice with regard to vaccinations is almost impossible, because for most travel vaccinations the immunogenicity and safety profile is unknown.

Research addressing the immunogenicity and safety of vaccines in different autoimmune inflammatory diseases treated with different immunosuppressive medications is urgently needed to allow giving evidence based vaccine advice.

In this observational study the immunogenicity and safety of tetanus booster and hepatitis A vaccinations will be assessed in AIIRD patients. The immune response will be evaluated as a function of the underlying disease and the possible influence of commonly used immunosuppressive drugs on the immune response will be studied.

Rationale for studying tetanus booster and hepatitis A vaccine Tetanus vaccination is one of the most frequently recommended vaccinations, and the effect of a booster vaccination can be addressed. Hepatitis A vaccine is the most widely used travel vaccine. Despite their importance, only very limited data are available for tetanus and hepatitis A vaccine in this patient group. By focusing on these vaccines the study will lead the way to the evaluation of further vaccines.

The purpose of this study is to determine whether tetanus and hepatitis A vaccinations are as immunogenic and safe in AIIRD patients as in healthy controls.

Detailed Description

The study will be placed in 6 rheumatology clinics in Switzerland and in 4 travel medicine clinics. Consecutive subjects with rheumatoid arthritis, spondylarthritis (ankylosing spondylitis), vasculitis (ANCA associated vasculitis and Behçet's disease) and healthy controls will be recruited.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2013-08-22
• Study First Submitted QC: 2013-09-19
• Study First Posted: 2013-09-20
• Study Start: 2013-10
• Primary Completion: 2015-12
• Status Verified: 2016-02
• Study Completion: 2016-02
• Last Update Submitted: 2016-02-24
• Last Update Posted: 2016-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 645

Inclusion Criteria

• Indication for hepatitis A and/or tetanus vaccination according to Swiss Federal Office of Public Health recommendations
• Male and female rheumatic patients with rheumatoid arthritis or axial spondyloarthritis (ankylosing spondylitis, axial psoriatic arthritis, axial undifferentiated spondyloarthritis, enteropahtic arthritis) or peripheral psoriatic arthritis or vasculitis (Behçet's disease or ANCA-associated vasculitis) or male and female healthy participants ≥ 18 years
• Signed Informed Consent after being informed

Read More

Exclusion Criteria

• Known hypersensitivity to a vaccine ingredient
• Estimated patient survival below 1 year
• Active malignant or active infectious disease
• Drug/alcohol abuse
• Insufficient understanding of local language

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with axial spondylarthritis	Hepatitis A vaccine and tetanus vaccine	If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
Patients with rheumatoid arthritis	Hepatitis A vaccine and tetanus vaccine	If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
Healthy controls	Hepatitis A vaccine and tetanus vaccine	If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
Patients with vasculitis	Hepatitis A vaccine and tetanus vaccine	If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.

Primary Outcome Measures

Name	Time	Method
Immunogenicity of hepatitis A and tetanus vaccination in patients with rheumatoid arthritis, axial spondyloarthritis and vasculitis and in healthy controls	Change from Baseline in geometric mean antibody titre and seroprotection at 4 weeks and at 12 weeks	comparison of the geometric mean antibody titre and percentage of seroprotected individuals after tetanus and hepatitis A vaccination between each disease group and healthy controls

Secondary Outcome Measures

Name	Time	Method
Safety of tetanus and hepatitis A vaccines in patients with rheumatoid arthritis, axial spondyloarthritis and vasculitis and in healthy controls	Activation of rheumatic disease will be assessed for 1 week after vaccine administration and at 4 and 12 weeks compared to baseline	Number of patients with any worsening or reactivation of the rheumatic disease after vaccine administration; Number of participants with adverse vaccine reactions (local and systemic reactions) in patients with rheumatoid arthritis, axial spondyloarthritis and vasculitis and in healthy controls

Trial Locations

Locations (10)

Swiss Tropical and Public Health Institute; 🇨🇭 Basel, Basel Town, Switzerland

University of Bern, Inselspital, Division of Infectious Diseases and Travel Medicine; 🇨🇭 Bern, Switzerland

Cantonal Hospital St. Gallen, Division of Rheumatology; 🇨🇭 St. Gallen, Switzerland

University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Divison of Infectious Diseases; 🇨🇭 Zürich, Switzerland

University of Geneva, University Hospitals, Division of Rheumatology; 🇨🇭 Geneva, Switzerland

University of Geneva, University Hospitals, Service de Médecine Tropicale et Humanitaire; 🇨🇭 Geneva, Switzerland

University Hospital of Basel, Rheumatology Division; 🇨🇭 Basel, Basel Town, Switzerland

Cantonal Hospital Aarau, Division of Rheumatology; 🇨🇭 Aarau, Aargau, Switzerland

University of Bern, Inselspital, Division of Rheumatology; 🇨🇭 Bern, Switzerland

University of Zurich, University Hopsital, Divison of Rheumatology; 🇨🇭 Zürich, Switzerland